SGLT2 inhibitors for teens with early kidney disease
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether a type of medicine called SGLT2 inhibitors can help teenagers with early-stage chronic kidney disease. It looks at how safe and effective these drugs are for slowing down kidney damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 14 and 18 years old
- You live in Aguascalientes
- You have a moderate amount of protein in your urine
- Your kidneys are still working fairly well
- Your kidney disease is not caused by another condition like diabetes or lupus
- A kidney biopsy shows a specific type of damage
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a daily medication can slow down kidney damage in people with type 1 diabetes who already have some kidney problems. It may help protect your kidneys from getting worse.
This Phase 3 trial studies the safety of an SGLT2 inhibitor (a diabetes medication that can affect kidney fluid handling) in people on peritoneal dialysis. The goal is to see how the treatment works in your type of dialysis and whether it causes any problems.
This trial tests dapagliflozin, a daily medicine, to slow kidney problems in people with early-stage chronic kidney disease caused by Alport syndrome. It may help protect kidney function and reduce worsening over time.
This trial tests a medication called SGLT2 inhibitor (a type of diabetes drug that may also help protect the kidneys) in children with chronic kidney disease. It aims to see if the drug is safe and easy to use in children ages 2–18 with moderate to severe kidney problems.
This trial tests whether SGLT2 inhibitor drugs can protect kidney function in people with advanced chronic kidney disease who are not yet on dialysis. It may help slow further kidney decline.
This study tests whether SGLT2 inhibitors (a type of diabetes drug that also helps kidneys) can help patients with acute kidney disease. It may be an option if you have diabetes or chronic kidney disease along with acute kidney problems.
Hear when a new Albuminuria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.